Cytokinetics to Participate in March Investor Conferences

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) has announced its participation in three major investor conferences this March 2025. The company's leadership will be present at:

• The Leerink Global Biopharma Conference on March 10, featuring a fireside chat with CEO Robert I. Blum and CCO Andrew Callos at 11:20 AM ET in Miami Beach
• The Jefferies Biotech on the Beach Summit on March 11, with management conducting one-on-one meetings
• The Barclays 27th Annual Global Healthcare Conference on March 12, including a fireside chat at 1:30 PM ET

All events will take place in Miami Beach, FL. Live webcasts of the fireside chats will be available on the Cytokinetics website's Investors & Media section, with replays archived for 90 days.

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:

• Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Monday, March 10, 2025 at 11:20 AM Eastern Time at the W South Beach Hotel in Miami Beach, FL.
• Jefferies Biotech on the Beach Summit: Management will participate in one-on-one meetings on Tuesday, March 11, 2025 at the Ritz Carlton South Beach Hotel in Miami Beach, FL.
• Barclays 27th Annual Global Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Wednesday, March 12, 2025 at 1:30 PM Eastern Time at the Loews Miami Beach Hotel in Miami Beach, FL.
  

Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a leading muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a pioneer in muscle and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

What investor conferences will Cytokinetics (CYTK) attend in March 2025?

Cytokinetics will attend three conferences: Leerink Global Biopharma Conference (March 10), Jefferies Biotech on the Beach Summit (March 11), and Barclays 27th Annual Global Healthcare Conference (March 12), all in Miami Beach.

How can investors access Cytokinetics (CYTK) conference presentations in March 2025?

Investors can access live webcasts of the fireside chats through the Investors & Media section at www.cytokinetics.com. Replays will be available for 90 days after the events.

Which Cytokinetics (CYTK) executives will present at the March 2025 conferences?

CEO Robert I. Blum and CCO Andrew Callos will participate in fireside chats at the Leerink and Barclays conferences.

What is the schedule for Cytokinetics (CYTK) presentations at the March 2025 conferences?

Presentations are scheduled for March 10 at 11:20 AM ET (Leerink), March 11 (Jefferies one-on-one meetings), and March 12 at 1:30 PM ET (Barclays).